Canine appendicular (limb) osteosarcoma is an aggressive cancer that causes local bone destruction and spreads easily to other organs. Better therapies are needed to prevent or delay this spread and extend lives. Cornell University College of Veterinary Medicine, in conjunction with the Comparative Oncology Trial Consortium, is offering a new clinical trial to help treat dogs with osteosarcoma.

GOALS
The purpose of this study is to enroll dogs with newly diagnosed osteosarcoma to compare standard of care therapy (SOC) to SOC therapy with the addition of a new drug. The goal is to determine the ability of this investigational drug to delay the cancer from spreading to other organs.

ELIGIBILITY
Dogs must be newly diagnosed with appendicular osteosarcoma by histology or cytology and have received no prior therapy (chemotherapy, radiation therapy, or bisphosphonate administration). Dogs should have measurable disease of a limb that is able to be surgically removed via amputation, and there can be no evidence of metastasis at time of enrollment. Initial evaluation and staging diagnostics must be performed at the Cornell University Hospital for Animals (CUHA) to determine final eligibility.

COMPENSATION
For enrolling in the clinical trial a $1,000 credit is provided for amputation. The study then covers office visits for scheduled appointments for chemotherapy and drug treatments; the chemotherapy and investigational drug and their associated administration costs; bloodwork at appointments to receive chemotherapy and investigational drug; hospitalization costs associated with blood measurements of the investigational drug; and x-rays at specific time intervals.

OWNER RESPONSIBILITIES
The owner is responsible for the initial office visit, staging diagnostics to determine eligibility, as well as any surgical costs above the credit. Owners must return to CUHA for follow-up appointments, chemotherapy and investigational drug visits. Owners must be willing to adhere to the administration and recording guidelines for the investigational drug at home. The owner is also responsible for post-chemotherapy bloodwork.

Principal Investigator
Angela McCleary-Wheeler, DVM, PhD, DACVIM
in conjunction with the Comparative Oncology Trials Consortium

Contact Information
(607) 253-3060
vet-research@cornell.edu